2020
The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms
Cui J, Qu Z, Harata-Lee Y, Shen H, Aung TN, Wang W, Kortschak RD, Adelson DL. The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms. PLOS ONE 2020, 15: e0236395. PMID: 32730293, PMCID: PMC7392229, DOI: 10.1371/journal.pone.0236395.Peer-Reviewed Original ResearchConceptsCore candidate genesCandidate pathwaysCandidate genesDifferential gene expression resultsGene expressionDNA replication/repairCompound Kushen InjectionTranscriptome-based analysisReplication/repairCancer cell linesEffect of CKITranscriptome data analysisCandidate molecular mechanismsCell cycle regulatorsMolecular changesCell linesGene expression resultsCell cycle phasesCell cycle arrestDE genesRegulatory relationshipsCycle regulatorsCell cycleMolecular mechanismsExpression results
2019
Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors